Navigation Links
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
Date:6/6/2009

Latest data on ultra rapid acting insulin presented at the American Diabetes Association's 69th Scientific Sessions

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia for adult patients with diabetes. The data were presented today at the American Diabetes Association's 69th Scientific Sessions.

"The unique pharmacokinetic profile of AFRESA allows this product to rapidly achieve peak insulin levels," said John Gerich, M.D., Program Director, Clinical Research Center, Department of Medicine, University of Rochester School of Medicine and Dentistry. "These results indicate that AFRESA may be a promising new therapy for patients with type 1 and type 2 diabetes, as it controls post meal-time glucose levels with the added benefits of less weight gain and lower risk of hypoglycemia."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Type 2 Study Design and Key Findings

Patients with type 2 diabetes who were inadequately controlled (A1C 7.0% and </=11.0%) despite insulin with/ without oral anti-hyperglycemic therapy were randomized to a 52-week course of either AFRESA
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
2. Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
3. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
4. VA Studies Advanced Prosthetic Arm
5. PARI Pharmas Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
6. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
7. AlphaVax Announces Promising Results in Melanoma Studies
8. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
9. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
10. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
11. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,, BASKINGRIDGE,N.J.,Nov.25/PRNewswire/--Rega...opmentofantithromboticaptamerswithactivecontrolage...llbepresentingatthePiperJaffray21stAnnualHealthCar....Mazzo,spresentationwillbegivenat1:10pm(EST)onTues...spipelinewithemphasisontheleaddevelopmentprogram,t...
(Date:11/25/2009)...,, UNIONCITY,Calif.,Nov.25/PRNewswire-FirstCa...mpanymanufacturingpoint-of-carebloodanalysissystem...executiveofficer,willpresentatthe21stAnnualPiperJa...9at2:00p.m.ET.TheconferencewillbeheldattheNewYorkP... Abaxisdevelops,manufacturesandmarketsportablebloo...
(Date:11/25/2009)...,, CHAPELHILL,N.C.,Nov.25/PRNewswire/--Cempra...rnandes,presidentandchiefexecutiveofficer,willpres...at8:50a.m.EST,December1,2009,atTheNewYorkPalaceHot...fthecompany,stwoleadingantibioticclinicalprogramsf...SA. ,, AboutCempraPharmaceuticals ,, Found...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 12824 1ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 12824 2ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 12824 3Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T cell Lymphoma 12823 1Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T cell Lymphoma 12823 2Presagia Launches Web Based Employee Leave Solution With Automated FMLA Workflow 50260 1Presagia Launches Web Based Employee Leave Solution With Automated FMLA Workflow 50260 2Presagia Launches Web Based Employee Leave Solution With Automated FMLA Workflow 50260 3
...N, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul...ne at Georgetown,University Medical Center, and pr...chem Inc.,s North American Phase III clinical tria...ay an update on,Neurochem,s investigational produc...se (AD). The presentation by Dr. Aisen will take,p...
...tabine achieved both primary and secondary endpoin... observed between,valopicitabine and ribavirin ~, ...all/ -- Idenix,Pharmaceuticals, Inc. today announc...ate triple combination therapy, consisting of,valo...or the,treatment of hepatitis C, pegylated interfe...
Other Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6
(Date:11/25/2009)... who were treated with cisplatin-based chemotherap...ical side effects and Raynaud-like phenomena, than...ding to a new study published online November 25 i..., Marianne Brydy, M.D., of the Department of Onc...orway, and colleagues conducted a cross-sectional ...
(Date:11/25/2009)...d arthritis, could help newly diagnosed diabetics,...lthDay News) -- A drug commonly used to treat non-...so shows some promise in helping patients newly di...imab (Rituxan), helped patients keep producing som...d destroyed some of their pancreatic beta cells, w...
(Date:11/25/2009)...ONSkincare ®isproudtosupportGNC,seffortstorai...t.Jude ThanksandGiving campaign,$1fromthepurchasep...Balm willbedonatedtoSt.Jude.Additionally,GNCcustom...eckoutatoneoftheir5,000+retaillocationsoratGNC.com...heir2009 ThanksandGiving campaign. ,, "Wearedel...
(Date:11/25/2009)...ccur in children with autism and related condition...es medication combined with a structured training ...researchers and their colleagues. , Published i...merican Academy of Child and Adolescent Psychiatry...te of Mental Health (NIMH) Research Units on Pedia...
(Date:11/25/2009)...e premier resource for life science careers and in...rest™ Hotbed Campaign this morning. , ...25, 2009 -- BioSpace.com, the premier resource for...e third edition of the BioForest™ Hotbed Cam...n is a promotional effort highlighting biotechnolo...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
... across the Yangtze River will take another two ye...ready changing the local weather, claim scientists... data suggest that the reservoir is cooling the Ya...ty of Maryland in College Park have collaborated w...
...consider home to be the safest place for deliverie...t their children immunised. The Gandhi M...egions of Udaipur district, conducted the study of...ording to the findings, around 94 percent of pregn...
...ons of insect love and desire. The cicada's songs ... how an emitting sex attracts conspecific members...though less conspicuous for us humans, are also si...thought to play a major role in the evolution of m...
..., Volodymyr Tarabara and Tom Voice, are leading an... Tarabara and Voice are leading an internatio...entists from two U.S. research universities, two r...nding of its kind a $2.5 million grant by the Na...
...e of humour or great look is whats really needed t...sing skills . A poll by online dating agenc...umped a lover because they were a miserable kisser... relationship. This was followed by using ...
...s drug dealer has revealed secrets about the singe... The singer and McFadden Kitten split two years ag... daughters Molly, 4, and Lilly Sue, 3. A...out drugs than anything in her life her children,...
Other Medicine News:Health News:China's Three Gorges Dam Changing Local Weather: Scientists 2Health News:Poor Health Practices Plague Rajasthan Tribal Women 2Health News:Another Sexual Attraction is Possible ... 2Health News:Two MSU Professors Spearhead International Water Project 2Health News:Two MSU Professors Spearhead International Water Project 3Health News:Drugs More Important Than Kids for Katona, Says Her Candy Man 2
...ities where space is a premium Fabius Tiro combine...gies with an ergonomic and compact design. Adding ...nfinity patient monitoring range allows you to cre...nd investment into the future. The open modular ar...
... using Datex-Ohmedas unique approach to anesthesia...laboration with clinicians. It combines the proven...eda monitoring technology into an affordable syste...world, ,The contemporary, compact design addresse...
...nt Wound Dressing is a sterile, single use bundle ...g applications. The synthetic matrix absorbs exce...ontours, and entraps slough and necrotic debris wi...rands of the matrix are bound together by a matrix...
...sician preference card system as well as a perpetu...management requirements of the surgical services d...h a broad array of inventory management capabiliti...e supply and charge capture workflow. Regardless o...
Medicine Products: